430PGEINOFOTE: SAFETY AND ACTIVITY ANALYSIS OF THE USE OF FOTEMUSTINE (FT) IN DIFFERENT SCHEDULES IN PROGRESSIVE GLIOBLASTOMA (GB) IN SPAIN

P. Perez Segura1, R.A. Manneh2, I. Ceballos3, A. Garcia Castano4, M. Benavides5, J. Fuster6, J.M. Cano7, M.A. Vaz8, J.P. Berros9, M. Covela10, V. Moreno11, T. Quintanar12, J.M. Garcia-Bueno13, I. Fernandez Perez14, O. Gallego15, P. Ramirez Daffos16, J. Espinos Jimenez17, S. Gonzalez18, S. Del Barco19, S. Ros20 Oncology, Hospital Clinico Universitario San Carlos, Madrid, SPAIN Medical Oncology, Hospital 12 de octubre, Madrid, SPAIN Medical Oncology, H U Canarias, Las Palmas de Gran Canaria, SPAIN Medical Oncology, Hospital Marques de Valdecilla, Santander, SPAIN Medical Oncology, Hospital Carlos Haya, Malaga, SPAIN Medical Oncology, Hospital Son Espasses, Palma de Mallorca, SPAIN Medical Oncology, Hospital General de Ciudad Real, Ciudad Real, SPAIN Medical Oncology, Hospital Ramon y Cajal, Madrid, SPAIN Medical Oncology, Hospital Central de Asturias, Oviedo, SPAIN Medcal Oncology, Hospital Lucus Augusti, Lugo, SPAIN Medical Oncology, Hospital La Paz, Madrid, SPAIN Medical Oncology, Hospital General de Elche, Elche, SPAIN Medical Oncology, Complejo Hospitalario Universitario de Albacete, Albacete, SPAIN Medical Oncology, Hospital Xeral Cies Vigo, Vigo, SPAIN Medical Oncology, Hospital Sant Pau, Barcelona, SPAIN Medical Oncology, Hospital Puerta del Mar, Cadiz, SPAIN Medical Oncology, Clinica Universitaria de Navarra, Pamplona, SPAIN Medical Oncology, Hospital Mutua Terrassa, Barcelona, SPAIN Medical Oncology, ICO, Gerona, SPAIN Medical Oncology, Hospital Virgen de la Arrixaca, Murcia, SPAIN